Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Deb U, Biswas S. Pretomanid: the latest USFDA-approved anti-tuberculosis drug. Indian J Tuberc. 2021;68:287–91.
2. Nguyen HT, Van Duong T, Jaw-Tsai S, Bruning-Barry R, Pande P, Taneja R, et al. Fed- and fasted-state performance of pretomanid amorphous solid dispersions formulated with an enteric polymer. Mol Pharm. 2023;20:3170–86.
3. Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, et al. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J Med Chem. 2010;53:855–66.
4. Dovprela (previously Pretomanid FGK)| European Medicines Agency [Internet]. https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk.
5. Winter H, Ginsberg A, Egizi E, Erondu N, Whitney K, Pauli E, et al. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. Antimicrob Agents Chemother. 2013;57:5516–20.